A record of what Nagaraj Shetti said publicly, with the source. Not advice.
“Recommends buying Zydus Lifesciences at ₹1,176, with a stop-loss of ₹1,123 and a target price of ₹1,268, for a 2-3 week timeframe. The downtrend appears to have reversed, forming a crucial bottom reversal pattern with expanding volumes and positive RSI.”
Nagaraj Shetti’s track record (trackable calls only): 139 graded calls · 95% CI 34–50%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
Entry: ₹1,176, as stated.
Target ₹1,268, stop ₹1,123, as stated.
Window: 21 days, the time frame the call states ("2-3 week").
Neither the target ₹1,268 nor the stop ₹1,123 was reached on a close by the end of the window. Miss.
The grader’s working: R3 TRADE_SETUP: entered ₹1176 on 2026-10-29 (stated entry ₹1176, LEVEL_CMP entry, filled); neither target nor stop reached by window end 2026-11-18. Window 21 days — rule H1: the quote states "2-3 week".
How it played out
How this is worked out- Target or stop first
- Neither the target nor the stop was reached on a close by the end of the window.
- Time to target
- The target was not reached on a close inside the window.
- Worst close against it
- No close was ever against the call up to 18 Nov 2026, when the call was decided. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.